What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors?

This clinical-stage biotech targeting kidney and metabolic diseases reported a notable insider sale, recent filings show.

CryptoAlerta — análise de criptomoedas e mercado em tempo real